BridgeBio stockholders approve officer exculpation amendment and 5M-share increase in stock plan

BridgeBio Pharma, Inc.

Stockholders elected all five Class III director nominees: Kumar, Homcy, Dachille, Daniels, Lo.
Approved amendment to increase shares reserved under 2021 Stock Plan by 5,000,000 shares (128.9M for, 26.7M against).
Approved officer exculpation amendment to limit liability of certain officers as permitted under Delaware law (151.2M for, 5.6M against).
Ratified Deloitte & Touche as independent auditor for FY2025 (173.8M for, 56k against).
Non-binding advisory vote on executive compensation passed (117.6M for, 37.9M against, 1.2M abstain).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BridgeBio Pharma, Inc.: Amendment to Certificate of Incorporation to include an officer exculpation provision limiting liability of certain officers as permitted by Delaware law (effective 2025-06-23).

Change: charter amendment
Effective: 2025-06-23

Exact text from the filing

an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate of Incorporation”) to limit the liability of certain officers of the Company as permitted under current Delaware law (the “Officer Exculpation Amendment”).

View on SEC.gov

27 governance changes filed in the last 30 days. Browse all governance changes →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-25-023362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.